| 摘要: |
| [摘要] 目的:探讨低分子肝素用于辅助治疗川崎病高凝状态的价值。方法:选择我院2014年1月至2017年1月确诊的川崎病
高凝状态住院患儿共102例,按是否接受低分子肝素治疗,分为观察组55例和对照组47例。观察组在丙种球蛋白及阿司匹林
治疗基础上加用低分子肝素治疗,对照组仅给予丙种球蛋白及阿司匹林治疗。治疗前后监测患儿凝血酶原时间(PT)、活化部
分凝血活酶时间(APTT)、凝血酶原国际标准化比值(INR)、纤维蛋白原(FIB)、D-二聚体水平、血沉(ESR)、血小板计数(PLT)、
红细胞压积(HCT)、高敏 C 反应蛋白(hs-CRP)的变化。 出院后随访6个月,心脏彩超观察冠脉损害情况。结果:治疗前两组患
儿血管炎症指标比较差异均无统计学意义(P均>0.05);治疗后两组患儿的 PLT、HCT、hs-CRP、ESR、FIB、D-二聚体均下降(P 均
<0.05),且观察组 PLT、hs-CRP、ESR、FIB、D-二聚体水平低于对照组(P 均<0.05)。 两组患儿均未出现明显出血倾向情况,观察
组冠脉损害发生率16.36% ,低于对照组的 34.04% (P<0.05)。 结论:低分子肝素作为川崎病高凝状态患儿的辅助治疗,在降
低血小板、抗炎、改善高凝状态、减少冠脉损害方面具有一定临床应用价值。 |
| 关键词: 低分子肝素 川崎病 高凝状态 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.04.005 |
|
| 基金项目: |
|
| Effect of Low Molecular Weight Heparin to Vascular Inflammation and Coronary Artery Lesion in Kawasaki Disease Combined with Hypercoagulability |
| Wang Xiang, Chen Zhi, Xiao Yunbing, Yang Zhou, Xiang Jinxing, Wang Yefeng |
| (Children' s Hospital of Hunan Province, Hunan Changsha 410007, China) |
| Abstract: |
| [Abstract] Objective: To investigate the value of low molecular weight heparin in Kawasaki disease combined with hypercoagulability.
Methods: There were 102 cases, of which 55 cases had been treated with IVIG, aspirin and low molecular heparin as observation
group, 47 cases treated with IVIG and aspirin as control group. The changes of PT, APTT, INR, FIB, D-dimmer, ESR, PLT, HCT,
and hs-CRP were monitored, and the discharged children were followed up for 6 months, the coronary arteries lesion was observed by
cardiac color ultrasound. Results: Before treatment, the comparison differences of vascular inflammation indexes were not statistically
meaningful (P>0.05). After treatment, PLT, HCT, hs-CRP, D dimmer, ESR, and FIB in observation group were significantly lower
than control group (P<0.05). The two groups had no obvious bleeding tendency, and the coronary arteries lesion incidence rate of the
observation group (16.36% ) was lower than that of the control group (34.04% ) (P<0.05). Conclusion: Low molecular weight
heparin is effective and safe in treatment of Kawasaki disease combined with hypercoagulability. |
| Key words: low weight molecular heparin Kawasaki disease hypercoagulability |
